Emeryville, Calif., Cambridge, Mass, Shanghai, China – January 22, 2019 – Berkeley Lights, Inc. (BLI), the leader in digital cell biology, announced today that Harbour BioMed, a global biopharmaceutical company has acquired the Beacon® Optofluidic platform to implement accelerated workflows for single-cell screening and analysis.
“Harbour BioMed is pleased to integrate the Berkeley Lights Beacon platform to further advance our monoclonal antibody discovery technology platforms. This would further enable us to speed up discovery and development, including single cell screening and profiling.” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. “It is an exciting phase in the history of Harbour BioMed as we look to further enhance our drug development capabilities to address unmet medical needs in patients across the globe.”
The Beacon platform is uniquely designed to carefully and specifically isolate, monitor, and assay almost any cell type. When used for antibody discovery, the Beacon platform can isolate and identify antibody-producing B-cells in less than one day, eliminating weeks of work. Once individual target cells are identified, the cells can be exported for sequencing or cloning. Each cell is tracked so that the phenotype can linked to the genotype. Harbour BioMed will be the first company in the Greater China region to equip and leverage the use of this pioneering technology.
“Berkeley Lights’ digital cell biology platform offers the diversity, applicability, and agility to meet the demands of today’s changing landscape of antibody discovery,” said Andy Last, Chief Commercial Officer at Berkeley Lights. “We are pleased to work with Harbour BioMed and have them join our growing list of companies incorporating the Beacon platform to accelerate drug discovery in the fast-growing antibody therapeutics market.”
To learn more about application of the Beacon platform, please click here.
About Harbour BioMed
Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases. The company’s discovery and development programs are built around its two patented transgenic mouse platforms for therapeutic antibody discovery. The company is building a proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. For more information, visit www.harbourbiomed.com.
About Berkeley Lights
Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development, and delivery of cell-based products and therapies.
At the intersection of biology, technology and information, our platforms automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. The Beacon platform* is ideally suited for cell line development, antibody discovery (including direct B-cell workflows), gene editing, and antibody engineering workflows. Each workflow provides a 100 fold increase in insights, 10 times faster, at a fraction of the cost.
For more information, visit http://www.berkeleylights.com/.
* For Research Use Only. Not for use in diagnostic procedures.